Hemoclot Uses

Rating: 5 - 1 review(s)
How do you administer this medicine?
sponsored

What is Hemoclot?

Hemoclot injection is used to control or prevent excessive or heavy bleeding during dental procedures in patients with hemophilia. Hemoclot is for short-term use only, usually 2 to 8 days.

Hemoclot injection is an antifibrinolytic agent. It works by blocking the breakdown of blood clots. It may also be used for other conditions as determined by your doctor.

Hemoclot is available only with your doctor's prescription.

Hemoclot indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

For short-term use (2-8 days) in haemophilia patients to reduce or prevent haemorrhage and to reduce the need for replacement therapy during and following tooth extraction.

For many haemostatic purposes including prevention of bleeding after surgery of trauma (eg, tonsillectomy and adenoidectomy, prostatic surgery, ocular trauma and cervical conisation), and to prevent rebleeding of subarachnoid haemorrhage, spontaneous bleeding in haemophilia and spontaneous or postoperative corneal oedema.

To treat primary or intrauterine device (IUD)-induced menorrhagia, gastric and intestinal haemorrhage, recurrent epistaxis and hereditary angioneurotic oedema. Hemoclot also inhibits induced hyperfibrinolysis during thrombolytic treatment with plasminogen activators.

How should I use Hemoclot?

Use Hemoclot as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Hemoclot.

Uses of Hemoclot in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Menstrual bleeding, heavy (oral): Treatment of cyclic heavy menstrual bleeding.

Tooth extraction in patients with hemostatic defects (injection, oral [Hemoclot; Canadian product]): Short-term use in hemophilia patients to reduce or prevent hemorrhage and reduce need for replacement therapy during and following tooth extraction.

Off Label Uses

Dental procedures in patients on oral anticoagulant therapy

Based on the American College of Chest Physicians guidelines for perioperative management of antithrombotic therapy, Hemoclot is recommended to use, when needed, in combination with the continuation of oral anticoagulant therapy for the perioperative management of patients who require minor procedures.

Hemoptysis (nonmassive), treatment

Data from a small, single-center, prospective, randomized, double-blind, placebo-controlled trial suggest that nebulized Hemoclot may be beneficial for the control of nonmassive hemoptysis by reducing the duration and volume of bleeding, with a low risk for side effects.

Hemoclot description

sponsored

Each capsule also contains sodium bisulfite, sodium lauryl sulfate and Yellow No.5 (Sunset Yellow FCF) as inactive ingredients. Each 5% w/v ampoule contains Tranexamic Acid 250 mg/5 mL, has a pH of 7-8 and an osmotic pressure ratio (with respect to physiological saline) of about 1.

Each 10% w/v ampoule contains Tranexamic Acid 250 mg/2.5 mL, has a pH of 7-8 and an osmotic pressure ratio (with respect to physiological saline) of about 2.

Hemoclot is trans-4-aminomethylcyclohexanecarboxylic acid. It has a molecular formula of C8H15NO2, molecular weight of 157.21 and melting point of 386-390°C (decomposition). It occurs as white crystals or powder, odorless and has bitter taste. It is freely soluble in water or glacial acetic acid; very slightly soluble in ethanol; practically insoluble in ether; soluble in sodium hydroxide TS.

Capsule Size: No.2, total length of 17.6 mm and weight of about 350 mg.

Hemoclot dosage

Hemoclot Dosage

Generic name: Hemoclot 100mg in 1mL

Dosage form: injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Immediately before tooth extraction in patients with hemophilia, administer 10 mg per kg body weight of Hemoclot intravenously together with replacement therapy. Following tooth extraction, intravenous therapy, at a dose of 10 mg per kg body weight three to four times daily, may be used for 2 to 8 days.

Note: For patients with moderate to severe impaired renal function, the following dosages are recommended:

Serum Creatinine (µmol/L) Hemoclot

Intravenous Dosage

120 to 250 (1.36 to 2.83 mg/dL) 10 mg/kg twice daily
250 to 500 (2.83 to 5.66 mg/dL) 10 mg/kg daily
>500 (>5.66 mg/dL) 10 mg/kg every 48 hours

or

5 mg/kg every 24 hours

For intravenous infusion, Hemoclot Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. Heparin may be added to Hemoclot Injection. Hemoclot Injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.

Single-dose vials and ampules

Discard Hemoclot vial or ampule and any remaining portion in the vial/ampule after single use.

The diluted mixture may be stored for up to 4 hours at room temperature prior to patient administration.

More about Hemoclot (Hemoclot)

Consumer resources

Professional resources

Related treatment guides

Hemoclot interactions

See also:
What other drugs will affect Hemoclot?

sponsored

Contraindications for Co-Administration: Hemoclot should not be co-adminstered with thrombin. Co-administration may cause a thrombosis tendency. It increases the tendency towards thrombosis due to the thrombogenic property of Hemoclot.

Precautions for Co-Administration: Hemoclot should be administered with care when co-administered with the following drugs.

Hemocoagulase: Co-administration at high doses may cause a thrombosis tendency. Due to the antiplasmin action of Hemoclot, fibrin clots formed by hemocoagulase may persist in the blood stream for a relatively long period of time, which may result in a prolonged thrombotic state.

Batroxobin: Co-administration may cause thromboembolism. Hemoclot inhibits the decomposition of desA fibrin polymer produced by batroxobin.

Coagulation Factor Agents (Eptacog-α): Coagulation may be further activated at sites with enhanced local fibrinolysis eg, the oral cavity. Coagulation factors exert hemostatic actions by activating the coagulation system, where as Hemoclot exerts hemostatic actions by inhibiting the fibrinolytic system.

Hemoclot side effects

See also:
What are the possible side effects of Hemoclot?

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Short-term Studies

The safety of Hemoclot Tablets in the treatment of heavy menstrual bleeding (HMB) was studied in two randomized, double-blind, placebo-controlled studies. One study compared the effects of two doses of Hemoclot Tablets (1950 mg and 3900 mg given daily for up to 5 days during each menstrual period) versus placebo over a 3-cycle treatment duration. A total of 304 women were randomized to this study, with 115 receiving at least one dose of 3900 mg/day of Hemoclot Tablets. A second study compared the effects of Hemoclot Tablets (3900 mg/day) versus placebo over a 6-cycle treatment duration. A total of 196 women were randomized to this study, with 117 receiving at least one dose of Hemoclot Tablets. In both studies, subjects were generally healthy women who had menstrual blood loss of ≥ 80 mL.

In these studies, subjects were 18 to 49 years of age with a mean age of approximately 40 years, had cyclic menses every 21-35 days, and a BMI of approximately 32 kg/m2. On average, subjects had a history of HMB for approximately 10 years and 40% had fibroids as determined by transvaginal ultrasound. Approximately 70% were Caucasian, 25% were Black, and 5% were Asian, Native American, Pacific Islander, or Other. Seven percent (7%) of all subjects were of Hispanic origin. Women using hormonal contraception were excluded from the trials.

The rates of discontinuation due to adverse events during the two clinical trials were comparable between Hemoclot Tablets and placebo. In the 3-cycle study, the rate in the 3900 mg Hemoclot Tablets dose group was 0.8% as compared to 1.4% in the placebo group. In the 6-cycle study, the rate in the Hemoclot Tablets group was 2.4% as compared to 4.1% in the placebo group. Across the studies, the combined exposure to 3900 mg/day Hemoclot Tablets was 947 cycles and the average duration of use was 3.4 days per cycle.

A list of adverse events occurring in ≥ 5% of subjects and more frequently in Hemoclot Tablets treated subjects receiving 3900 mg/day compared to placebo is provided in Table 2.

Long-term Studies

Long-term safety of Hemoclot Tablets was studied in two open-label studies. In one study, subjects with physician-diagnosed heavy menstrual bleeding (not using the alkaline hematin methodology) were treated with 3900 mg/day for up to 5 days during each menstrual period for up to 27 menstrual cycles. A total of 781 subjects were enrolled and 239 completed the study through 27 menstrual cycles. A total of 12.4% of the subjects withdrew due to adverse events. Women using hormonal contraception were excluded from the study. The total exposure in this study to 3900 mg/day Hemoclot Tablets was 10,213 cycles. The average duration of Hemoclot Tablets use was 2.9 days per cycle.

A long-term open-label extension study of subjects from the two short-term efficacy studies was also conducted in which subjects were treated with 3900 mg/day for up to 5 days during each menstrual period of up to 9 menstrual cycles. A total of 288 subjects were enrolled and 19% subjects completed the study through 9 menstrual cycles. A total of 2.1% of the subjects withdrew due to adverse events. The total exposure to 3900 mg/day Hemoclot Tablets in this study was 1,956 cycles. The average duration of Hemoclot Tablets use was 3.5 days per cycle.

The types and severity of adverse events in these two long-term open-label trials were similar to those observed in the double-blind, placebo-controlled studies although the percentage of subjects reporting them was greater in the 27-month study, most likely because of the longer study duration.

A case of severe allergic reaction to Hemoclot Tablets was reported in the extension trial, involving a subject on her fourth cycle of treatment, who experienced dyspnea, tightening of her throat, and facial flushing that required emergency medical treatment.

Postmarketing Experience

The following adverse reactions have been identified from postmarketing experience with Hemoclot. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Based on US and worldwide postmarketing reports, the following have been reported in patients receiving Hemoclot for various

Indications:

Hemoclot contraindications

See also:
What is the most important information I should know about Hemoclot?

Thromboembolic Risk

​Do not prescribe Hemoclot Tablets to women who are

Venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported with Hemoclot.

Hypersensitivity to Hemoclot

Do not prescribe Hemoclot Tablets to women with known hypersensitivity to Hemoclot.

Active ingredient matches for Hemoclot:

Tranexamic Acid in Philippines.

Etamsylate

Ethamsylate in India.


Unit description / dosage (Manufacturer)Price, USD
Hemoclot 250mg TAB / 10$ 0.63
Hemoclot 500mg TAB / 10$ 1.11
Hemoclot 500 mg x 100's$ 35.56
250 mg x 200's
500 mg x 200's
Hemoclot 500 mg Tablet$ 0.11
Hemoclot 250 mg Tablet$ 0.06
Hemoclot 250mg TAB / 200
Hemoclot 500mg TAB / 200
HEMOCLOT 250MG/250MG TABLET 1 strip / 10 tablets each (S V Biovac Pharmaceuticals Pvt Ltd)$ 0.30
HEMOCLOT tab 250 mg x 10's (Ethix HC)$ 0.63
HEMOCLOT tab 500 mg x 10's (Ethix HC)$ 1.11
Hemoclot 250 mg/250 mg Tablet (S V Biovac Pharmaceuticals Pvt Ltd)$ 0.03

List of Hemoclot substitutes (brand and generic names):

HEMODIL 250MG TABLET 1 strip / 10 tablets each (Dial Pharmaceuticals Pvt Ltd)$ 0.63
HEMOLATE Capsule/ Tablet / 500mg / 10 units (Micro Nova Pharmaceuticals Ltd.)$ 1.56
HEMOLATE Capsule/ Tablet / 250mg / 10 units (Micro Nova Pharmaceuticals Ltd.)$ 0.92
250 mg x 10's (Micro Nova Pharmaceuticals Ltd.)$ 0.92
500 mg x 10's (Micro Nova Pharmaceuticals Ltd.)$ 1.56
Hemolate 250mg TAB / 10 (Micro Nova Pharmaceuticals Ltd.)$ 0.92
Hemolate 500mg TAB / 10 (Micro Nova Pharmaceuticals Ltd.)$ 1.56
Hemolate 500 mg Tablet (Micro Nova Pharmaceuticals Ltd.)$ 0.16
Hemolate 250 mg Tablet (Micro Nova Pharmaceuticals Ltd.)$ 0.09
HEMOLATE tab 250 mg x 10's (Micro Nova Pharmaceuticals Ltd.)$ 0.92
HEMOLATE tab 500 mg x 10's (Micro Nova Pharmaceuticals Ltd.)$ 1.56
Hemolate 250mg TAB / 10 (Micro Nova Pharmaceuticals Ltd.)$ 0.92
Hemolate 500mg TAB / 10 (Micro Nova Pharmaceuticals Ltd.)$ 1.56
Hemolate 250mg Tablet (Micro Nova Pharmaceuticals Ltd.)$ 0.09
Hemostan 250 mg x 100's (Biomedis)$ 40.34
Hemostan 500 mg x 100's (Biomedis)$ 54.72
Hemostan 250 mg/2.5 mL x 5's (Biomedis)$ 17.01
Hemostan 500 mg/5 mL x 5's (Biomedis)$ 20.32
Hemostat 250mg TAB / 10 (Meridian Medicare Ltd.)$ 0.77
Hemostat 500mg TAB / 10 (Meridian Medicare Ltd.)$ 1.43
Hemostat 125mg INJ / 2ml (Meridian Medicare Ltd.)$ 0.33
250 mg x 10's (Meridian Medicare Ltd.)$ 0.77
500 mg x 10's (Meridian Medicare Ltd.)$ 1.43
125 mg x 2ml (Meridian Medicare Ltd.)$ 0.33
Hemostat 250 mg Tablet (Meridian Medicare Ltd.)$ 0.08
Hemostat 500 mg Tablet (Meridian Medicare Ltd.)$ 0.15
HEMOSTAT 125MG INJECTION 1 vial / 2 ML injection each (Meridian Medicare Ltd.)$ 0.40
HEMOSTAT 250MG TABLET 1 strip / 10 tablets each (Meridian Medicare Ltd.)$ 0.77
HEMOSTAT 500MG TABLET 1 strip / 10 tablets each (Meridian Medicare Ltd.)$ 1.59
HEMOSTAT tab 250 mg x 10's (Meridian Medicare Ltd.)$ 0.77
HEMOSTAT tab 500 mg x 10's (Meridian Medicare Ltd.)$ 1.43
HEMOSTAT inj 125 mg x 2ml (Meridian Medicare Ltd.)$ 0.33
Hemostat cap 500 mg 2 x 10's (Meridian Medicare Ltd.)
Hemostat cap 500 mg 3 x 10's (Meridian Medicare Ltd.)
Hemostat cap 500 mg 5 x 10's (Meridian Medicare Ltd.)
Hemostat inj 250 mg/5 mL 1's (Meridian Medicare Ltd.)
Hemostat inj 250 mg/5 mL 10 x 1's (Meridian Medicare Ltd.)
Hemostat inj 250 mg/5 mL 5 x 1's (Meridian Medicare Ltd.)
Hemostat 125mg Injection (Meridian Medicare Ltd.)$ 0.20
Hemostat 250mg Tablet (Meridian Medicare Ltd.)$ 0.08
Hemostat 500mg Tablet (Meridian Medicare Ltd.)$ 0.16
Hemostat Inj 250 mg Injection (Meridian Medicare Ltd.)$ 0.16
HEMOSTAT 2ML INJECTION 1 vial / 10 injections each (Meridian Enterprises Pvt Ltd)$ 0.32
HEMOSTIC 500MG INJECTION 1 vial / 2 ML injection each (Alembic Pharmaceuticals Ltd)$ 0.11
Hemostop 50 mg/1 mL x 10's (Navil Laboratories)
Hemostop 500 mg Tablet (Navil Laboratories)$ 0.14
Hemostop 250 mg Tablet (Navil Laboratories)$ 0.08
Hemotran 500 mg x 100's

References

  1. DailyMed. "TRANEXAMIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "tranexamic acid". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "tranexamic acid". http://www.drugbank.ca/drugs/DB00302 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Hemoclot are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hemoclot. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported useful

Was the Hemoclot drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users%
Useful1
100.0%


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


2 consumers reported age

Users%
16-292
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved